In this experiment, responses in the RV-WN/TBE prime-INV boost group were significantly higher than in INV primeCRV-WN/TBE boost group ( 0

In this experiment, responses in the RV-WN/TBE prime-INV boost group were significantly higher than in INV primeCRV-WN/TBE boost group ( 0.001; test). than candidates based on Langat E5, TBE, and yellow fever 17D backbones, and was found to be highly immunogenic and efficacious in mice. Live chimeric yellow fever 17D/TBE, Dengue 2/TBE, and Langat E5/TBE candidates were also constructed but were found to be underattenuated. RV-WN/TBE was demonstrated to be highly immunogenic in Rhesus macaques after a single dose, inducing a significantly more durable humoral immune response compared with three doses of a licensed, adjuvanted human inactivated vaccine. Its immunogenicity was not significantly affected by preexisting immunity against WN. Immunized monkeys were guarded from a stringent surrogate Rabbit Polyclonal to Histone H2A (phospho-Thr121) challenge. These results support the identification of a single-cycle TBE vaccine with a superior product profile to existing inactivated vaccines, which could lead to improved vaccine coverage and control of the disease. = 0.5; test) (Fig. 2 0.30; MannCWhitney test). Importantly, the reduction appeared to be less pronounced compared with the effect of YF 17D preimmunization on immunogenicity of YF/JE and YF/TBE viruses (Fig. S1), suggesting that anti-vector immunity should not be a concern for Acetyl-Calpastatin (184-210) (human) RepliVax-TBE in humans. We also investigated in mice whether RV-WN/TBE and INV vaccines could be interchangeable in prime-boost vaccination regimens (Table S1). In this experiment, a single dose of INV induced low TBE-specific N Ab titers and provided only 60% protection from TBE challenge, whereas a second dose of INV significantly increased the titers (PRNT50 GMT 1,019 on day 42) resulting in 100% protection. RV-WN/TBE was efficient in prime-boost vaccination regimens when used alone or in combination with INV. The highest PRNT50 titers were observed in INV primeCRV-WN/TBE boost, RV-WN/TBE primeCRV-WN/TBE boost, and Acetyl-Calpastatin (184-210) (human) RV-WN/TBE primeCINV boost groups (GMTs 3,287, 6,291, and 14,205, respectively). Animals in all groups primed or boosted with RV-WN/TBE were protected from challenge (Table S1). In this experiment, responses in the RV-WN/TBE prime-INV boost group were significantly higher than in INV primeCRV-WN/TBE boost group ( 0.001; test). This obtaining Acetyl-Calpastatin (184-210) (human) requires further evaluation in NHP. In these experiments, we also decided that TBE challenge resulted in a several-fold increase of TBE-specific N Ab titers in sera of immunized mice, indicative of an anamnestic response. Attenuation, Immunogenicity, and Efficacy in NHP. Schedules of studies in Rhesus monkeys are illustrated in Figs. S2CS4. Because monkeys do not develop clinical disease following peripheral TBE virus infection, a Acetyl-Calpastatin (184-210) (human) surrogate challenge model was first established. Animals were inoculated by the s.c. route with 6 log10 FFU of LGT T1674, LGT TP21 or YF/TBE viruses followed by measuring viremia on days 1C8. Only animals inoculated with the LGT T1674 virus developed readily detectable, uniform viremia with GMTs of 3.2 and 2.1 log10 FFU/mL on days 1 and 2, respectively (Fig. S5 0.05, MannCWhitney test), and two and three complete i.m. (the route used in humans) doses of the INV control (GMT 3,313 on day 29 after two doses and 4,111 on day 50 after three doses) (Table 3). A single 7 log10 dose of RV-WN/TBE by the i.m. route was also highly effective (GMTs 955 and 722 on days 29 and 50). However, a single s.c. 7 log10 dose of RV-WN/TBE induced a lower Ab response (e.g., GMT 232 on day 50; = 0.004, MannCWhitney test), albeit substantially boosted by a second s.c. dose (GMT 2,832 on day 50). We also tested the effectiveness of RV-WN/TBE at lower i.d. doses of 6 and 5 log10 FFU. These doses also induced appreciable N Ab responses, although significantly lower compared with a 7 log10 i.d. dose. Protective efficacy was first demonstrated by challenging vaccinated animals with LGT T1674 virus (5 log10 FFU, s.c.) on day 51 or 59 after vaccination, and measuring postchallenge viremia. Standard titration of virus in monkey sera revealed that all mock immunized control animals had detectable viremia with mean peak titers of up to 3 log10 FFU/mL on day 2 (Fig. S5 0.05, MannCWhitney test) (Table 3). Importantly, no postchallenge viremia was detected in this group, and thus the animals were completely guarded (Fig. 3 0.03; MannCWhitney test). The RV-WN/TBE vaccinated animals were guarded from challenge performed at 6 mo, whereas a detectable postchallenge viremia was.